The goal of the Clinical Core is to: (1) assist in clinical trial design; (2) maintain the appropriate regulatory infrastructure and ensure compliance at the local, state, and federal levels for proposed and future clinical trials; (3) interface and data transfer to the private CRO and National PEGT data management specialists. Patients in three clinical trials will be treated at Stanford University or The Children's Hospital of Philadelphia. While record keeping will ultimately be the responsibility of the center in which the patient is treated, Stanford University will serve as the lead Center for maintaining the overall organizational framework of the trials through the Core. While the GCRC at Stanford University will serve as the physical site of the Clinical Core, participants from both institutions are represented. A description of the GCRC at Stanford and a brief summary of the GCRC at CHOP follows. The duties of the clinical core is described herein.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-C (S2))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Margaritis, Paris (2010) Long-term expression of canine FVIIa in hemophilic dogs. Thromb Res 125 Suppl 1:S60-2
Margaritis, Paris; Roy, Elise; Aljamali, Majed N et al. (2009) Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 113:3682-9
Bedi, Maninder S; Alvarez Jr, Rene J; Kubota, Toru et al. (2008) Myocardial Fas and cytokine expression in end-stage heart failure: impact of LVAD support. Clin Transl Sci 1:245-8
Aljamali, Majed N; Margaritis, Paris; Schlachterman, Alexander et al. (2008) Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 118:1825-34
Akache, Bassel; Grimm, Dirk; Shen, Xuan et al. (2007) A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther 15:330-9
Chen, Jian; Wu, Qi; Yang, Pingar et al. (2006) Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Mol Ther 13:260-9
Bedi, Maninder; McNamara, Dennis; London, Barry et al. (2006) Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm 3:808-12
Grimm, Dirk; Pandey, Kusum; Nakai, Hiroyuki et al. (2006) Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 80:426-39
Inagaki, Katsuya; Fuess, Sally; Storm, Theresa A et al. (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14:45-53
Manno, Catherine S; Arruda, Valder R; Pierce, Glenn F et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-7

Showing the most recent 10 out of 36 publications